Company intelligence / Profile preview

Cellevate

Ownership: Private
Employees: ~16
Development stage: Commercial

Overview

Cellevate has developed the first nanofiber microcarrier for gene therapy applications, providing up to sixty times more surface area for cell growth than conventional systems. Initial results show significant potential to increase yields and productivity in upstream bioprocessing of gene therapies. The company completed technical and commercial readiness in Q3/Q4 of 2024 and began pre-launch activities at CPHI Milan in October. No clinical trial data as the company does not develop drugs.

Modalities: Device (cell culture system)Nanofiber-based platform technology (enabling cell and gene therapy manufacturing)Microcarrier (for bioprocessing/gene therapy production)
Industry: Chemicals & Materials

Partnerships

Industrifonden (investor)European Innovation Council Fund (EIC Fund) (investor)No major pharma partnerships disclosed yet.

Beyond the preview

Go deeper on Cellevate.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellevate.

Explore the full profile